We discovered that BITC treatment alters phosphorylation status of extracellular-signal-regulated kinase (ERK), p53 and proline-rich Akt substrate of 40 kDa (PRAS40) in breast cancer cells. The gene discussed is AKT1S1; the disease is breast carcinoma.